CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 1,202 enrolled / 1,202 target
Drug / intervention
Influenza ModRNA Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06436703
NCT06436703Phase 1CompletedOn Track (47.5/mo)Completion was 16mo ago

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS

Pfizer·interventional·Posted May 31, 2024·Updated Jun 12, 2026

In Brief

A Phase 1 clinical trial evaluating Influenza ModRNA Vaccine and Quadrivalent Influenza Vaccine (QIV) for Influenza, Human. Completed, enrolled 1,202 participants across 32 sites.

Detailed Summary

The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are: * safe; and * how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as harmful or foreign. RNA (also called ribonucleic acid) is one of two types of nucleic acid made by cells. RNA contains information that has been copied from DNA (the other type of nucleic acid). Cells make several different forms of RNA, and each form has a specific job in the cell. Many forms of RNA have functions related to making proteins. RNA is also the genetic material of some viruses instead of DNA. RNA can be made in the laboratory and used in research studies. Also called ribonucleic acid. Influenza is term used for flu illness. It is an infection caused by a virus that affects your mouth, nose, and throat. The study is seeking for participants who: * are at least 18 years of age * have not received an influenza vaccine within the last 6 months * are generally healthy This study will be divided into three sub-studies: Substudy A (SSA), Substudy B (SSB), and Substudy C (SSC). All participants, regardless of sub-study, will receive 1 dose of either of the following vaccines as an injection into their arm: * 1 of the modRNA influenza vaccines that is being studied; or * an approved influenza vaccine approved for use in their respective age group. Participants will be involved in this study for about 6 months. During this time, participants will have at least 3 clinic visits.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedMay 31, 2024
Enrollment StartMay 23, 2024
Primary CompletionFeb 5, 2025
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.1 years ago

Arms & Interventions

SSA: Influenza ModRNA Vaccine 2Aexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSA: Influenza ModRNA Vaccine 3Aexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSA: Influenza ModRNA Vaccine 4Aexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSA: Influenza ModRNA Vaccine 5Aexperimental

\- Single dose on Day 1

Biological: Influenza ModRNA Vaccine
SSA: QIV1active_comparator

\- Single dose on Day 1

Biological: Quadrivalent Influenza Vaccine (QIV)
SSB: Influenza ModRNA Vaccine 3Bexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSB: Influenza ModRNA Vaccine 4Bexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSB: Influenza ModRNA Vaccine 5Bexperimental

\- Single dose on Day 1

Biological: Influenza ModRNA Vaccine
SSB: QIV2active_comparator

\- Single Dose on Day 1

Biological: Quadrivalent Influenza Vaccine (QIV)
SSB: QIV3active_comparator

\- Single Dose on Day 1

Biological: Quadrivalent Influenza Vaccine (QIV)
SSC: Influenza ModRNA Vaccine 3Cexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSC: Influenza ModRNA Vaccine 4Cexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSC: Influenza ModRNA Vaccine 5Cexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSC: Influenza ModRNA Vaccine 6Cexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSC: Influenza ModRNA Vaccine 7Cexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSC: Influenza ModRNA Vaccine 8Cexperimental

\- Single Dose on Day 1

Biological: Influenza ModRNA Vaccine
SSC: Influenza ModRNA Vaccine 9Cexperimental

\- Single dose on Day 1

Biological: Influenza ModRNA Vaccine
SSC: QIV2active_comparator

\- Single Dose on Day 1

Biological: Quadrivalent Influenza Vaccine (QIV)
SSC: QIV3active_comparator

\- Single Dose on Day 1

Biological: Quadrivalent Influenza Vaccine (QIV)

Interventions

Influenza ModRNA Vaccinebiological

Intramuscular injection

Quadrivalent Influenza Vaccine (QIV)biological

Intramuscular injection